-
公开(公告)号:GEP20033130B
公开(公告)日:2003-07-10
申请号:GEAP2000004561
申请日:2000-03-17
Applicant: VERTEX PHARMA
Inventor: STAMOS DEAN , TRUDEAU MARTIN , BETHIEL SCOTT , BADIA MICHAEL , SAUNDERS JEFFREY , RONKIN STIVEN
IPC: C07C275/40 , C07D307/20 , A61K31/27 , A61K31/275 , A61K31/341 , A61K31/421 , A61K31/422 , A61K31/454 , A61K31/5377 , A61K31/541 , A61K45/00 , A61P1/18 , A61P9/10 , A61P11/06 , A61P19/02 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/02 , A61P43/00 , C07C275/42 , C07D263/32 , C07D413/12 , C07D417/12 , C07F9/653
Abstract: 1. Technical Result Obtaining new compounds inhibiting IMPDH. 2. Essence The present invention relates to compounds, which inhibit IMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds. 3. Field of Application Medicine.
-
公开(公告)号:AR029341A1
公开(公告)日:2003-06-25
申请号:ARP000101205
申请日:2000-03-17
Applicant: VERTEX PHARMA
Inventor: STAMOS DEAN , TRUDEAU MARTIN , BETHIEL SCOTT , RONKIN STEVEN M , BADIA MICHAEL , SAUNDERS JEFFREY
IPC: C07D307/20 , A61K31/27 , A61K31/275 , A61K31/341 , A61K31/421 , A61K31/422 , A61K31/454 , A61K31/5377 , A61K31/541 , A61K45/00 , A61P1/18 , A61P9/10 , A61P11/06 , A61P19/02 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/02 , A61P43/00 , C07C275/40 , C07C275/42 , C07D263/32 , C07D413/12 , C07D417/12 , C07F9/653 , C07C275/34 , A61K31/277 , A61P37/00
Abstract: Un compuesto inhibidor de la enzima IMPDH que tiene, la formula (A) en donde: cada uno de r1 y R2 es seleccionado independientemente entre hidrogeno; -CF3; -[alquilo(C1-6) de cadena recta o ramificada]; -[alquilo(C1-6) de cadena recta o ramificada]-R7; -[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada]; -[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada]-R7 o ûR7; y en donde al menos uno de R1 o R2 es û[alquilo (C1-6) de cadena recto o ramificada]ûR7; -[alquenilo (c2-6) o alquinilo (C2-6) de cadena recto o ramificada]ûR7 o ûR7 en donde hasta 4 átomos de hidrogeno en cualquiera de dichos alquilo, alquenilo o alquinilo son opcionalmente e independientemente reemplazados por R3; y en donde uno o ambos de R1 o R2 son esterificados opcionalmente para formar una prodroga; o en donde R1 y R2 alternativamente forman conjuntamente tetrahidrofuranilo, en donde R9 es hidrogeno, (R)-metilo, (R)-etilo o (R)-hidroximetilo, un átomo de hidrogeno en dicho tetrahidrofurano es reemplazado por ûOR6 o ûR7 y en donde R9 es (S)ûmetilo, (S)-etilo o (S)-hidroximetilo , un átomo de hidrogeno en dicho tetrahidrofurano es reemplazado opcionalmente por ûOR6 o -R7, en donde si R9 es hidrogeno, (R)-metilo, (R)-etilo o (R)-hidroximetilo y cada uno de R1 y R2 son independientemente hidrogeno, -[alquilo(C1-6) no sustituido de cadena recta o ramificada], o -[alquenilo(C2-6) o alquinilo (C2-6) no sustituidos de cadena recta o ramificada], entonces la porcion del compuesto representada por ûCH(R1)R2 es un alquilo (C5-12), alquenilo (C5-12) o alquinilo (C5-12) de cadenas rectas o ramificadas; cada R3 es seleccionado independientemente entre halo, CH, -OR4 o ûN(R5)2; R4 es seleccionado entre hidrogeno, -[alquilo(C1-6) de cadena recta o ramificada], -[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada], [alquilo (C2-6) de cadena recta o ramificada]-R7, -[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada]-R7, -C(O)-[alquilo (C1-6) de cadena recta o ramificada] ûC(O)-[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada], -C(O)-[alquilo(C1-6) de cadena recta o ramificada]-N(R8)2, -C(O)-[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada]-N(R8)2, -P(O)(OR8)2, -P(O)(OR8)(R8), -C(O)-R7, -S(O)2N(R5)2, -[alquilo(C1-6) de cadena recta o ramificada]ûCN, o -[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada]-CN; Cada R5 es seleccionado independientemente entre hidrogeno, -[alquilo (C1-6) de cadena recta o ramificada], -[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada], -[alquilo (C1-6) de cadena recta o ramificada]-R7, -[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada ]-R7, -[alquilo (C1-6) de cadena recta o ramificada] ûR7, -[alquilo (C1-6) de cadena recta o ramificada]ûCN, -[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada]-CN, -[alquilo(C1-6) de cadena recta o ramificada]-OR4, -[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada]ûOR4, -C(O)-[alquilo (C1-6) de cadena recta o ramificada], -C(O)-[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada], -C(O)-R7, -C(O)O-R7,-C(O)O- [alquilo(C1-6) de cadena recta o ramificada], -C(O)O-[alquenilo(C2-6) o alquinilo(C2-6) de cadena recta o ramificada], -S(O)2-[alquilo(C1-6) de cadena recta o ramificada], o ûS(O)2-R7; o dos porciones R5, si están ligados al mismo átomo de nitrogeno, forman conjuntamente con dicho átomo de nitrogeno un anillo heterocíclico de 3 a 7 miembros, en donde dicho anillo heterocíclico contiene opcionalmente 1 a 3 heteroátomos adicionales seleccionados independientemente de N; O, S, S(O)2; R6 es seleccionado entre ûC(O)-CH3, CH2-C(O)-OH, -CH2-C(O)-O-tBu, -CH2-CN o CH2-CsCH; cada R7 es un sistema anular monocíclico o bicíclico, en donde en dicho sistema anular: i) cada anillo comprende 3 a 7 átomos en el anillo seleccionado independientemente entre C, N, O o S; ii) no más de 4 átomos del anillo son seleccionados entre N, O o S; iii) cualquier CH2 es reemplazado opcionalmente con C(O); iv) cualquier S es reemplazado opcionalmente con S(O) o S(O)2; cada R8 es seleccionado independientemente entre hidrogeno o û [alquilo(C1-4) de cadena o ramificada]; en donde en cualquier sistema anular en dicho compuesto hasta 3 átomos de hidrogeno ligados a los átomos del anillo son reemplazados opcionalmente e independientemente con halo, hidroxi, nitro, ciano, amino, -[alquilo (C1-4) de cadena recta o ramificada]; o-[alquilo (C1-4) de cadena recta o ramificada], -[alquenilo (C2-4) o alquinilo (C2-4) de cadena recta o ramificada], o O-[alquenilo(C2-6) o alquinilo (C2-4) de cadena recata o ramificada]; y en donde cualquier sistema anular es opcionalmente benzofusionado; R9 es seleccionado entre hidrogeno, (R)-metilo, (S)-metilo, (R)-etilo, (S)ûetilo, (R)-hidroximetilo o (S)-hidroximetilo; R10 es seleccionado entre ûCsN o 5 oxazolilo; y R11 es seleccionado entre halo, -O-[alquilo (C1-3) de cadena recta o ramificada] o ûO-[alquenilo (C2-3) o alquinilo(C2-3) de cadena recta o ramificada].
-
公开(公告)号:EE200100492A
公开(公告)日:2002-12-16
申请号:EEP200100492
申请日:2000-03-17
Applicant: VERTEX PHARMA
Inventor: STAMOS DEAN , TRUDEAU MARTIN , BETHIEL SCOTT , BADIA MICHAEL , SAUNDERS JEFFREY
IPC: C07D307/20 , A61K31/27 , A61K31/275 , A61K31/341 , A61K31/421 , A61K31/422 , A61K31/454 , A61K31/5377 , A61K31/541 , A61K45/00 , A61P1/18 , A61P9/10 , A61P11/06 , A61P19/02 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/02 , A61P43/00 , C07C275/40 , C07C275/42 , C07D263/32 , C07D413/12 , C07D417/12 , C07F9/653 , A61K31/277 , C07C275/34
Abstract: The present invention relates to compounds which inhibit JMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting JMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention also relates to methods for inhibiting the activity of I1VIPDH using the compounds of this invention and related compounds.
-
公开(公告)号:TR200103428T2
公开(公告)日:2002-04-22
申请号:TR200103428
申请日:2000-03-17
Applicant: VERTEX PHARMA
Inventor: STAMOS DEAN , TRUDEAU MARTIN , BETHIEL SCOTT , BADIA MICHAEL , SAUNDERS JEFFREY
IPC: C07D307/20 , A61K31/27 , A61K31/275 , A61K31/341 , A61K31/421 , A61K31/422 , A61K31/454 , A61K31/5377 , A61K31/541 , A61K45/00 , A61P1/18 , A61P9/10 , A61P11/06 , A61P19/02 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/02 , A61P43/00 , C07C275/40 , C07C275/42 , C07D263/32 , C07D413/12 , C07D417/12 , C07F9/653 , A61K31/277 , C07C275/34
Abstract: The present invention relates to compounds which inhibit JMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting JMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention also relates to methods for inhibiting the activity of I1VIPDH using the compounds of this invention and related compounds.
-
公开(公告)号:AU3757700A
公开(公告)日:2000-10-09
申请号:AU3757700
申请日:2000-03-17
Applicant: VERTEX PHARMA
Inventor: STAMOS DEAN , TRUDEAU MARTIN , BETHIEL SCOTT , BADIA MICHAEL , SAUNDERS JEFFREY
IPC: C07D307/20 , A61K31/27 , A61K31/275 , A61K31/341 , A61K31/421 , A61K31/422 , A61K31/454 , A61K31/5377 , A61K31/541 , A61K45/00 , A61P1/18 , A61P9/10 , A61P11/06 , A61P19/02 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/02 , A61P43/00 , C07C275/40 , C07C275/42 , C07D263/32 , C07D413/12 , C07D417/12 , C07F9/653 , A61K31/277 , C07C275/34
Abstract: The present invention relates to compounds which inhibit JMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting JMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention also relates to methods for inhibiting the activity of I1VIPDH using the compounds of this invention and related compounds.
-
公开(公告)号:ES2405316T3
公开(公告)日:2013-05-30
申请号:ES00916479
申请日:2000-03-17
Applicant: VERTEX PHARMA
Inventor: STAMOS DEAN , TRUDEAU MARTIN , BETHIEL SCOTT , BADIA MICHAEL , SAUNDERS JEFFREY
IPC: C07C275/42 , C07D307/20 , A61K31/27 , A61K31/275 , A61K31/341 , A61K31/421 , A61K31/422 , A61K31/454 , A61K31/5377 , A61K31/541 , A61K45/00 , A61P1/18 , A61P9/10 , A61P11/06 , A61P19/02 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/02 , A61P43/00 , C07C275/40 , C07D263/32 , C07D413/12 , C07D417/12 , C07F9/653
Abstract: Un compuesto de fórmula (IA): **Fórmula** en donde: uno de R1 o R2 se selecciona de hidrógeno, etilo o fenilo; y el otro de R1 o R2 se selecciona de -CH2OH, -CH2CN, -CH2CH2CN o -CH2N(CH2CH3)2, o R1 y R2 se toman juntos para formar un anillo 3-tetrahidrofuranilo;R9 se selecciona de (S)-metilo, (S)-etilo o (S)-hidroximetilo; R10 se selecciona de -C≡N o 5-oxazolilo; y R11 se selecciona de halo, -O-alquilo lineal de (C1-C3), u -O-alquenilo o alquinilo lineal de (C2-C3).
-
公开(公告)号:CA2367017C
公开(公告)日:2009-05-26
申请号:CA2367017
申请日:2000-03-17
Applicant: VERTEX PHARMA
Inventor: STAMOS DEAN , BETHIEL SCOTT , BADIA MICHAEL , TRUDEAU MARTIN , SAUNDERS JEFFREY , RONKIN STEVEN
IPC: C07D263/32 , C07D307/20 , A61K31/27 , A61K31/275 , A61K31/277 , A61K31/341 , A61K31/421 , A61K31/422 , A61K31/454 , A61K31/5377 , A61K31/541 , A61K45/00 , A61P1/18 , A61P9/10 , A61P11/06 , A61P19/02 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/02 , A61P43/00 , C07C275/40 , C07C275/42 , C07D413/12 , C07D417/12 , C07F9/653
Abstract: The present invention relates to compounds of formula (A) which inhibit IMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.
-
18.
公开(公告)号:BG65563B1
公开(公告)日:2008-12-30
申请号:BG10602001
申请日:2001-10-16
Applicant: VERTEX PHARMA
Inventor: STAMOS DEAN , TRUDEAU MARTIN , BETHIEL SCOTT , BADIA MICHAEL , SAUNDERS JEFFREY
IPC: C07D307/00 , C07D307/20 , A61K31/27 , A61K31/275 , A61K31/341 , A61K31/421 , A61K31/422 , A61K31/454 , A61K31/5377 , A61K31/541 , A61K45/00 , A61P1/18 , A61P9/10 , A61P11/06 , A61P19/02 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/02 , A61P43/00 , C07C275/40 , C07C275/42 , C07D263/32 , C07D413/12 , C07D417/12 , C07F9/653
Abstract: The invention relates to compounds, which inhibit the IMPDH enzyme, as well as to pharmaceutical compositions comprising such compounds. The compounds and the pharmaceutical compositions are used for inhibiting IMPDH-mediated processes; therefore they can be used for prevention and treatment of IMPDH-related troubles.
-
公开(公告)号:OA11848A
公开(公告)日:2006-03-08
申请号:OA1200100235
申请日:2000-03-17
Applicant: VERTEX PHARMA
Inventor: BADIA MICHAEL , BETHIEL SCOTT , SAUNDERS JEFFREY , STAMOS DEAN , TRUDEAU MARTIN
IPC: C07D307/20 , A61K31/27 , A61K31/275 , A61K31/341 , A61K31/421 , A61K31/422 , A61K31/454 , A61K31/5377 , A61K31/541 , A61K45/00 , A61P1/18 , A61P9/10 , A61P11/06 , A61P19/02 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/02 , A61P43/00 , C07C275/40 , C07C275/42 , C07D263/32 , C07D413/12 , C07D417/12 , C07F9/653 , A61K31/277 , C07D275/34
Abstract: The present invention relates to compounds which inhibit JMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting JMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention also relates to methods for inhibiting the activity of I1VIPDH using the compounds of this invention and related compounds.
-
公开(公告)号:NZ514540A
公开(公告)日:2003-11-28
申请号:NZ51454000
申请日:2000-03-17
Applicant: VERTEX PHARMA
Inventor: STAMOS DEAN , TRUDEAU MARTIN , BETHIEL SCOTT , BADIA MICHAEL , SAUNDERS JEFFREY
IPC: C07D307/20 , A61K31/27 , A61K31/275 , A61K31/341 , A61K31/421 , A61K31/422 , A61K31/454 , A61K31/5377 , A61K31/541 , A61K45/00 , A61P1/18 , A61P9/10 , A61P11/06 , A61P19/02 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/02 , A61P43/00 , C07C275/40 , C07C275/42 , C07D263/32 , C07D413/12 , C07D417/12 , C07F9/653 , C07C275/34
Abstract: A phenyl derivative has the formula (A) wherein: each of R1 and R2 is independently hydrogen, -CF3, alkyl, alkenyl, alkynyl, alkyl-R7, alkenyl-R7, alkynyl-R7 or -R7, provided at least one of R1 or R2 is alkyl-R7, alkenyl-R7, alkynyl-R7 or -R7; wherein up to 4 hydrogen atoms in any of the alkyl, alkenyl or alkynyl are optionally replaced by R3, or one or both of R1 or R2 are optionally esterified to form a prodrug or R1 and R2 are alternatively taken together to form tetrahydrofuranyl, when R9 is hydrogen, (R)-methyl, (R)- ethyl or (R)-hydroxymethyl, one hydrogen atom in the tetrahydrofuran is replaced by -OR6 or -R7, and when R9 is (S)- methyl, (S)-ethyl or (S)-hydroxymethyl, one hydrogen atom in the tetrahydrofuran is optionally replaced by -OR6 or -R7 or when R9 is hydrogen, (R)-methyl, (R)-ethyl or (R)- hydroxymethyl and each of R1 and R2 are independently hydrogen, unsubstituted alkyl, or unsubstituted alkenyl or alkynyl, then the portion of the compound represented by - CH(R1)R2 is a C5-12 alkyl, alkenyl or alkynyl; each R3 is independently halo, CN, -OR4, or -N(R5)2; R4, R5, R6 and R8 are as defined in the specification, each R7 is a monocyclic or bicyclic ring system wherein each ring system comprises 3 to 7 ring atoms independently selected from C, N, O and S, no more than 4 ring atoms are selected from N, O or S, any CH2 is optionally replaced with C (O) and any S is optionally replaced with S(O) or S(O)2; R9 is hydrogen, (R)-methyl, (S)-methyl, (R)-ethyl, (S)- ethyl, (R)-hydroxymethyl or (S)-hydroxymethyl; R10 is -C=N or 5-oxazolyl, and R11 is halo, -O-alkyl, or -O-alkenyl or -O-alkynyl. The compounds are useful for treating or preventing an inosine-5'-monophosphate dehydrogenase disease or condition.
-
-
-
-
-
-
-
-
-